Parkinson's disease: Diagnosis

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Brooks, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; MRI; Parkinson; PET; SPECT; Transcranial sonography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANATOMICAL VARIATION; BRAIN ATROPHY; CEREBRAL PEDUNCLE; DIFFUSION COEFFICIENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; HUMAN; MIDDLE CEREBRAL PEDUNCLE; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATIAL DOPAMINE DEFICIENCY; SUBSTANTIA NIGRA; SUPERIOR CEREBELLAR PEDUNCLE ATROPHY; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN VENTRICLE DILATATION; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; LEWY BODY; MIDDLE CEREBELLAR PEDUNCLE; PARKINSONISM; PONS; PUTAMEN; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SUBCORTEX; SUPERIOR CEREBELLAR PEDUNCLE; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

EID: 84858640659     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70012-8     Document Type: Review

References (22)

1. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, et al. Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord 2011;26:1997-2003.
2. Tambasco N, Belcastro V, Sarchielli P, Floridi P, Pierguidi L, Menichetti C, et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol 2011;18:471-7.
3. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-84.
4. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-9.
5. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003;60:74-7.
6. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-5.
7. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-31.
8. Stockner H, Sojer M, K KS, Mueller J, Wenning GK, Schmidauer C, et al. Midbrain sonography in patients with essential tremor. Mov Disord 2007;22:414-7.
9. Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, Daniel SE, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998 Jul;65:65-71.
10. Morelli M, Arabia G, Salsone M, Novellino F, Giofre L, Paletta R, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011;26:527-33.
11. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002 Feb 26;58:575-80.
12. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003 Mar 25;60:922-7.
13. Nicoletti G, Lodi R, Condino F, Tonon C, Fera F, Malucelli E, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-87.
14. Paviour DC, Thornton JS, Lees AJ, Jager HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007;22:68-74.
15. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: The [123I]-FP-CIT Study Group. Mov Disord 2000 May;15:503-10.
16. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61: 1224-9.
17. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123IIoflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175-82.
18. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year followup in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006;27:933-7.
19. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Successful antiparkinsonian medication withdrawal in patients with parkinsonism and normal FP-CIT SPECT. Mov Disord 2006;21:2247-50.
20. Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, et al. Differential diagnosis of parkinsonism with [18F]Fluorodeoxyglucose and PET. Mov Disord 1998;13:268-74.
21. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26: 912-21.
22. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, et al. 123Iiodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de-novo parkinsonism. Neurology 1992;42:556-61.